










© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society 
of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 
Pure viral sepsis secondary to Community-Acquired Pneumonia in adults: risk and 
prognostic factors 
 
Catia Cillóniz, PhD1, Cristina Dominedò, MD2, Daniel Magdaleno3, Miquel Ferrer, MD1, 
Albert Gabarrús, MSc1, Antoni Torres, MD1 
1Department of Pneumology, Hospital Clinic of Barcelona; August Pi i Sunyer 
Biomedical Research Institute - IDIBAPS, University of Barcelona; Biomedical Research 
Networking Centers in Respiratory Diseases (Ciberes) Barcelona, Spain. 
2Department of Anesthesiology and Intensive Care Medicine, Fondazione Policlinico 
Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy. 




Correspondence: Prof. Antoni Torres (primary) or Dr Catia Cillóniz (alternative) 
Department of Pulmonary Medicine, Hospital Clinic of Barcelona 
C/ Villarroel 170, 08036 Barcelona, Spain 
Tel: (+34) 93-227-5779, fax: (+ 34) 93-227-9813 
Email: atorres@clinic.cat (primary) or catiacilloniz@yahoo.com (alternative) 
 
Summary: Pure viral sepsis affected 3% of all patients admitted with a diagnosis of 
community-acquired pneumonia and 19% of those admitted to intensive care unit. 
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We investigated the risk and prognostic factors of pure viral sepsis in adult patients 
with community-acquired pneumonia (CAP), using the Sepsis-3 definition. Pure viral 
sepsis was found in 3% of all patients admitted to the emergency department with a 
diagnosis of CAP (138 out of 4,028), 19% of all CAP patients admitted to the intensive 
care unit (ICU) (138 out of 722) and 61% of all patients with a diagnosis of viral CAP 
(138 out of 225). Our data indicate that males and patients aged ≥65 years are at 
increased risk of viral sepsis.  
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Improvements in molecular diagnostic techniques have increasingly shown a high 
prevalence of viral pneumonia over recent years. Globally, it is now estimated that 100 
million cases of viral pneumonia occur annually, with the incidence varying by 
seasonality, geographic location, and age group[1]. Respiratory viruses are detected as 
etiological agents in almost one-third of cases of community-acquired pneumonia 
(CAP)[2–5] and account for 7% - 36% of patients with severe CAP and a defined 
microbial etiology[2,3]. Recently, Jain et al.[2] analyzed 2,320 cases of pneumonia 
detected by intensive microbiological diagnosis, including viral molecular techniques. A 
microbial etiology was identified in 853 (38%) cases. The three main causes were 
respiratory viruses (23%), bacteria (11%), and co-infections (3%), indicating the clear 
prominence of viral etiology. CAP is often complicated by sepsis, which is a 
multifactorial process for which staging is necessary to provide personalized 
treatments that target individual needs[6]. Viral sepsis has been defined as a severe 
inflammatory response to viral infection[7], and unlike bacterial sepsis, its prevalence 
in adults with CAP is unknown. 
We aimed to investigate the prevalence, risks and prognostic factors associated with 
pure viral sepsis in adult patients with CAP, using the Third International Consensus 
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We performed a retrospective observational study of consecutive adult patients with a 
diagnosis of CAP admitted to the Hospital Clinic of Barcelona from the emergency 
department between 2005 and 2017. We excluded non-hospitalized patients, patients 
with severe immunosuppression, active tuberculosis, viral bacterial co-infections, and 
unavailable data. We selected patients with pure viral CAP and compared those with 
and without sepsis. Severe CAP was defined according to the ATS/IDSA guidelines[8]. 
Sepsis was defined as the presence of pneumonia and an increase of ≥2 points in the 
Sequential Organ Failure Assessment score [6]. Respiratory viruses were diagnosed by 
serology, immunofluorescence assay (IFA), and isolation in cell cultures from 2005 to 
2007. However, diagnosis was performed by polymerase chain reaction (PCR) and/or 
culture of nasopharyngeal swab samples from 2008 to 2017. Two independent nested 
multiplex real-time PCR tests were used to detect human influenza viruses (A, B, and 
C), respiratory syncytial virus, adenoviruses, parainfluenza viruses (1–4), coronaviruses 
(229E and OC43), enteroviruses, and rhinoviruses (A, B, and C). The criteria for 
etiological diagnosis are available in a previous report[3]. The main clinical outcome 
was in-hospital mortality. Secondary outcomes included length of hospital stay, ICU 
admission, ICU mortality, length of ICU stay, need for mechanical ventilation, 30-day 
mortality, and 1-year mortality. Patients were followed for one year. For publication 
purposes, the study was approved by the Ethics Committee of our institution (Comité 
Ètic d’Investigació Clínica, register: 2009/5451). The need for written informed consent 
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Logistic regression analyses were used to examine the association between sepsis and 
risk factors. First, each risk factor was tested individually. Then, all risk factors that 
showed an association in the univariate model (p<0.10) were added to the 
multivariable model. Finally, a backward stepwise selection (pin<0.05, pout>0.10) was 
used to determine factors associated with sepsis. 
Generalized linear model analyses were performed to determine the influence of the 
risk factors on in-hospital mortality. Models were defined using a binomial probability 
distribution and a logit link function, using inverse probability of treatment weights 
(IPTWs) to account for biases due to observed confounders. First, each risk factor was 
tested individually. Second, a propensity score (PS) for patients with sepsis was 
developed. IPTW used the PS to form a weight. Finally, the weight and the year of 
admission were incorporated in the multivariable weighted logistic regression model 
for in-hospital mortality, including all risk factors which showed an association in the 
univariate analyses (p<0.10), and calculated in a stepwise backward elimination 
procedure. 
We used the multiple imputation method for missing data in the multivariable 
analyses. 
The level of significance was set at 0.05 (two-tailed). All analyses were performed using 
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We identified 4,028 consecutive patients admitted to the emergency department with 
a diagnosis of CAP during the study period; 2,760 patients (68%) were hospitalized and 
225 (8%) of them were found to have a pure viral CAP; 36 (23%) of them showed 
severe CAP. 
Descriptive data of the overall population 
Among the 225 cases of pure viral CAP, the most common respiratory viruses were 
influenza A virus (52%; n=118), rhinovirus (13%; n=30), respiratory syncytial virus (10%; 
n=23), parainfluenza virus (8%; n=18), adenovirus (8%; n=16), influenza B virus (7%; 
n=15), and coronavirus (2%; n=4). We did not observe any change in the prevalence of 
viral CAP over the study period (p=0.65). The mean (SD) age was 66 (19) years and 126 
(56%) were males. Most patients (66%; n=146) had at least one comorbidity, with 
chronic respiratory disease (37%) and diabetes mellitus (22%) being the most frequent. 
Despite bacterial pathogens were not isolated, patients received empiric antibiotic 
therapies. Monotherapy was reported in 84 patients (40%): fluoroquinolones and -
lactams were the most common agents administered; 127 patients (60%) received a 
combination therapy, with the most frequent association being a -lactam plus a 
macrolide (27%; n=56) and a -lactam plus a fluoroquinolone (26%; n=54). 
The median (Q1; Q3) length of hospital stay was 7 (5; 12) days, in-hospital mortality 
was 7% (n=16). A total of 43 patients (19%) were admitted to ICU, 23 (53%) of whom 
required mechanical ventilation; the median length of ICU stay was 7 (4; 12) days, and 
ICU mortality was 7% (n=3). Thirty-day mortality was 4% (n=10), and 1-year mortality 
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Comparison of the sepsis and non-sepsis groups 
Among all patients diagnosed with pure viral CAP, 138 (61%) presented with sepsis and 
9 (7%) with septic shock at admission. Table 1 summarizes the main clinical 
characteristics. The sepsis group included patients who were older, more frequently 
males, and had more comorbidities (especially chronic respiratory diseases) compared 
with the non-sepsis group. There was no statistically significant difference in symptoms 
(fever, cough, pleuritic pain, purulent expectoration or dyspnoea) between the two 
groups. At admission, patients in the sepsis group presented with elevated respiratory 
rate and lower lymphocyte levels more frequently than patients in the non-sepsis 
group. There was no statistically significant difference in the distribution of respiratory 
viruses between the two groups. Thus, we did not find any association between the 
type of virus and the presence or absence of sepsis (non-sepsis group: influenza virus 
59% (n=51), non-influenza virus 41% (n=36) vs. sepsis group: influenza virus 59% 
(n=82), non-influenza virus 41% (n=56); p>0.99). More patients in the sepsis group 
were classified as having a Pneumonia Severity Index IV–V, indicating severe CAP.  
Overall, 92 patients (41%) received antiviral therapy with Oseltamivir. The percentage 
of antiviral therapy was similar between the two groups (47% vs. 42%, p=0.43). Forty-
four patients (33%) with sepsis were treated with empiric antibiotic monotherapy. The 
sepsis group received fluoroquinolone-based monotherapy less frequently than the 
non-sepsis group (27% vs. 44%, p=0.008). Antimicrobial therapy was inappropriate 
(non-concordant with published guidelines) in 4 cases (3%) in the sepsis group, but 
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Risk factors for viral sepsis 
Among the variables associated with viral sepsis in the univariate logistic regression 
analysis, age ≥65 years and male sex remained independent risks factors for viral sepsis 
in the multivariable analysis (Table 2). Internal validation of the logistic regression 
model using bootstrapping with 1,000 samples demonstrated robust results for all the 
variables included in the model, with small 95% CIs around the original coefficients. 
Outcomes 
No statistically significant difference was observed between the two groups in terms of 
in-hospital mortality, ICU mortality, length of ICU stay, 30-day mortality, and 1-year 
mortality (Table 1). However, patients with sepsis showed longer length of hospital 
stay, were more frequently admitted to ICU and needed more frequently invasive 
mechanical ventilation than patients without sepsis.  
Factors associated with in-hospital mortality 
In the propensity-adjusted logistic regression multivariable analysis of in-hospital 
mortality using the weighted data, after excluding patients with septic shock at 
admission and with do-not-resuscitate orders, pure viral sepsis was not associated with 
in-hospital mortality (OR 0.77, 95% CI 0.18 to 3.17). All variables remained significant 
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This study has three main findings. First, pure viral sepsis defined according to the 
Sepsis-3 criteria was found in 3% of all patients admitted with a diagnosis of CAP, 19% 
of those admitted to ICU, and 61% of those diagnosed with pure viral CAP. Second, 
male sex and age ≥65 years were shown to be risk factors for pure viral sepsis. Third, 
pure viral sepsis was not found to be a risk factor for in-hospital mortality.  
Sepsis is a life-threatening organ dysfunction due to an overwhelmed host response to 
an infection. Although respiratory viruses are reported to be important causative 
agents of severe CAP[9], the prevalence of pure viral sepsis is not fully known. A 
recently published study investigated the role of virus detection through multiplex PCR 
from the nasopharynx of clinically septic patients during a winter season[10]. The 
authors reported that respiratory viruses, including influenza A virus, human 
metapneumovirus, coronavirus, and respiratory syncytial virus were detected in 70% 
of adult patients with sepsis. In another research, Montull et al.[11] investigated the 
predictors of severe sepsis in CAP patients, reporting that 38% of patients presented 
with severe sepsis and that 0.5% were identified to have respiratory viruses as casual 
agents. The proportion of patients with pure viral sepsis was slightly higher in our 
study population, but we think that this was due to our use of the new Sepsis-3 
definition. Montull et al. also highlighted the association between older age and 
development of viral sepsis, which was in line with our finding that viral sepsis affected 
64% of patients (n=88) aged ≥65 years. These results are consistent with data showing 
that elderly patients, due to the increased prevalence of chronic conditions and age-
related changes in the immune system, are more susceptible to infectious diseases and 
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was another risk factor for pure viral sepsis, consistent with data that men typically 
have more chronic comorbidities and a higher incidence of CAP than women[13]. 
We observed that viral sepsis was not a risk factor for in-hospital mortality in patients 
without septic shock. Our data support those of previous studies in which respiratory 
viruses have frequently been found in critically ill patients with pneumonia, but where 
mortality rates were not significantly different in patients with bacterial infection or 
viral infection, [9,10,14]. This highlights the need to identify patients at higher risk of 
viral sepsis and the importance of a complete microbiological diagnosis in CAP. We 
could not find other studies addressing the issue of pure viral sepsis (defined according 
to the Sepsis-3 criteria) in CAP in a large inpatient adult cohort.  
Finally, we observed that 41% of patients with viral CAP received Oseltamivir therapy, 
without differences between patients with or without sepsis. Compared to other 
previous studies[5,15], our population received a higher proportion of antiviral 
therapy. However, future studies are needed to investigate why antiviral therapy 
among patients hospitalized with CAP is not high since current guidelines strongly 
recommend early treatment with Oseltamivir in patients with influenza[8]. 
Some limitations must be addressed. First, although the protocol used for CAP 
diagnosis in our hospital has not changed significantly during the 12 years study, we 
cannot discount the effect of changes in microbiological diagnosis over this period. 
Second, regarding microbiological diagnosis, more rapid PCR diagnostic tests for 
influenza virus and respiratory syncytial virus were used during the influenza season. 
Third, the indications for Oseltamivir therapy were only extended in 2009, before 
which it was only used to treat severe cases of viral infection. 
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of viral CAP, supporting the importance of stratifying patients risk for viral sepsis and 







/jid/advance-article-abstract/doi/10.1093/infdis/jiz257/5494607 by Sandy Lem
m















We are indebted to all medical and nursing colleagues for their assistance and 
cooperation in this study. 
Notes 
Financial support: This study was supported by Ciber de Enfermedades Respiratorias 
(CibeRes CB06/06/0028), and 2009 Support to Research Groups of Catalonia 911; 
IDIBAPS. Dr Cilloniz is the recipient of a Postdoctoral Grant (Strategic plan for research 
and innovation in health-PERIS 2016-2020) and SEPAR fellowship 2018. 









/jid/advance-article-abstract/doi/10.1093/infdis/jiz257/5494607 by Sandy Lem
m















1.  Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet 2011; 
377:1264–1275.  
2.  Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring 
Hospitalization among U.S. Adults. N Engl J Med 2015; 373:415–427.  
3.  Cillóniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired 
pneumonia and its relation to severity. Thorax 2011; 66:340–346.  
4.  Burk M, El-Kersh K, Saad M, Wiemken T, Ramirez J, Cavallazzi R. Viral infection in 
community-acquired pneumonia: a systematic review and meta-analysis. Eur 
Respir Rev 2016; 25:178–188.  
5.  Radovanovic D, Sotgiu G, Jankovic M, et al. An international perspective on 
hospitalized patients with viral community-acquired pneumonia. Eur J Intern Med 
2019; 60:54–70.  
6.  Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus 
Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315:801–810.  
7.  Gupta N, Richter R, Robert S, Kong M. Viral Sepsis in Children. Front Pediatr 2018; 
6. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153324/. 
Accessed 30 December 2018. 
8.  Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of 
America/American Thoracic Society consensus guidelines on the management of 
community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27-
72.  
9.  Choi S-H, Hong S-B, Ko G-B, et al. Viral infection in patients with severe 
pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med 
2012; 186:325–332.  
10.  Ljungström LR, Jacobsson G, Claesson BEB, Andersson R, Enroth H. Respiratory 
viral infections are underdiagnosed in patients with suspected sepsis. Eur J Clin 
Microbiol Infect Dis 2017; 36:1767–1776.  
11.  Montull B, Menéndez R, Torres A, et al. Predictors of Severe Sepsis among 
Patients Hospitalized for Community-Acquired Pneumonia. PLoS ONE 2016; 
11:e0145929.  
12.  Bermejo-Martin JF, Martín-Fernandez M, López-Mestanza C, Duque P, Almansa R. 
Shared Features of Endothelial Dysfunction between Sepsis and Its Preceding Risk 
Factors (Aging and Chronic Disease). J Clin Med 2018; 7.  
13.  Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired 






/jid/advance-article-abstract/doi/10.1093/infdis/jiz257/5494607 by Sandy Lem
m














14.  Karhu J, Ala-Kokko TI, Vuorinen T, Ohtonen P, Syrjälä H. Lower respiratory tract 
virus findings in mechanically ventilated patients with severe community-
acquired pneumonia. Clin Infect Dis 2014; 59:62–70.  
15.  Oboho IK, Bramley A, Finelli L, et al. Oseltamivir Use Among Children and Adults 









/jid/advance-article-abstract/doi/10.1093/infdis/jiz257/5494607 by Sandy Lem
m














Table 1. Patients characteristics and outcomes according to the presence of viral sepsis 




(N = 87) 
Yes 
(N = 138) 
 
p-valuea 
Age, mean (SD), years 61 (22) 69 (17) 0.004 
Age ≥65 years, n (%) 38 (44) 88 (64) 0.003 
Male sex, n (%) 40 (46) 86 (62) 0.016 
Current smoker, n (%) 16 (19) 32 (23) 0.42 
Current alcohol consumer, n (%) 9 (10) 13 (9) 0.80 
Previous antibiotic, n (%) 27 (33) 40 (31) 0.67 
Influenza vaccine, n (%) 32 (39) 56 (45) 0.41 
Pneumococcal vaccine, n (%) 12 (15) 26 (20) 0.28 
Previous inhaled corticosteroids, n (%) 9 (11) 25 (19) 0.11 
Previous systemic corticosteroids, n (%) 5 (6) 7 (5) >0.99 
Previous episode of pneumonia, n (%) 8 (10) 24 (18) 0.10 
Comorbidities, n (%)b 46 (54) 100 (73) 0.004 
  Chronic respiratory disease 24 (29) 57 (43) 0.044 
  Chronic cardiovascular disease 9 (11) 16 (12) 0.81 
  Diabetes mellitus 13 (16) 35 (26) 0.076 
  Neurological disease 10 (12) 26 (19) 0.15 
  Chronic renal disease 2 (2) 11 (8) 0.076 
  Chronic liver disease 5 (6) 4 (3) 0.30 
Nursing-home, n (%) 6 (7) 12 (9) 0.66 
Cough, n (%) 69 (81) 116 (85) 0.50 
Purulent sputum, n (%) 43 (52) 79 (59) 0.35 
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(N = 87) 
Yes 
(N = 138) 
 
p-valuea 
Pleuritic pain, n (%)  23 (28) 31 (23) 0.47 
Fever, n (%) 74 (86) 102 (76) 0.059 
Respiratory rate, median (IQR), rpm 22 (20; 24) 24 (24; 30) <0.001 
C-reactive protein, median (IQR), mg/Dl 16.4 (6.0; 25.7) 16.3 (7.8; 24.4) 0.89 
Lymphocytes, median (IQR), cell/mm3 1,026 (636; 1,612) 819 (535; 1,330) 0.039 
Microbial etiology    
  Influenza A virus, n (%) 46 (53) 72 (52) 0.92 
  Rhinovirus, n (%) 12 (14) 18 (14) 0.87 
  Respiratory syncitial virus, n (%) 11 (13) 12 (10) 0.34 
  Parainfluenza virus (1-3), n (%) 4 (5) 14 (11) 0.14 
  Adenovirus, n (%) 5 (6) 11 (8) 0.53 
  Influenza B virus, n (%) 5 (6) 10 (7) 0.66 
  Coronavirus, n (%) 3 (4) 1 (1) 0.30 
  Other respiratory viruses, n (%) 1 (1) 0 (0) 0.39 
PSI score, median (IQR) 63 (43; 90) 97 (74; 119) <0.001 
PSI risk class IV–V, n (%)c 8 (24) 52 (58) 0.001 
Severe CAP, n (%)d 4 (7) 32 (31) <0.001 
Pleural effusion, n (%) 8 (11) 9 (7) 0.34 
Multilobar, n (%) 23 (26) 35 (25) 0.86 
Septic shock at admission, n (%) 0 (0) 9 (7) 0.013 
Do-not-resuscitate order, n (%) 2 (3) 10 (8) 0.14 
Length of hospital stay, median (IQR), days 6 (4; 10) 9 (6; 14) <0.001 
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(N = 87) 
Yes 
(N = 138) 
 
p-valuea 
  ICU mortality, n (%)e 0 (0) 3 (8) >0.99 
  Length of ICU stay, median (IQR), dayse 7 (4; 22) 7 (4; 11) 0.60 
Mechanical ventilation, n (%)f   0.007 
  Not ventilated 67 (97) 93 (82) 0.002 
  Non-invasive 1 (1) 10 (9) 0.055 
  Invasive 1 (1) 11 (10) 0.032 
In-hospital mortality, n (%) 5 (6) 11 (8) 0.54 
30-day mortality, n (%) 5 (6) 5 (4) 0.51 
1-year mortality, n (%) 6 (7) 11 (8) 0.78 
Abbreviations: CAP indicates community acquired pneumonia; ICU, intensive care unit; IQR, 
interquartile range; PSI, pneumonia severity index; SD, standard deviation. Percentages 
calculated on non-missing data. a Categorical variables were compared using the χ2 test or the 
Fisher exact test. Continuous variables were compared using the t test or the nonparametric 
Mann-Whitney U test. b May have >1 comorbid condition. c Stratified according to 30-day 
mortality risk for community-acquired pneumonia: classes I–III (≤90 points) have low mortality 
risk and classes IV–V (>90 points) have the highest mortality risk. d Severe CAP was defined 
according to the ATS/IDSA major and minor criteria. e 7 patients in the no sepsis group and 36 
patients in the sepsis group were used to calculate the percentages. f Patients who initially 
received non-invasive ventilation but needed subsequently intubation were included in the 
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Table 2. Significant risk factors for pure viral sepsis in the logistic regression analyses 
(N = 225) 
 Univariatea Multivariableb 
Variable OR 95% CI P-value OR 95% CI P-value 
Age ≥65 years 2.27 1.31 to 3.92 0.003 2.59 1.46 to 4.58 0.001 
Male sex 1.94 1.13 to 3.35 0.017 2.26 1.28 to 4.01 0.005 
Chronic pulmonar 
disease 
  0.037 
- - - 
  No 1 - - - - - 
  Bronchiectasis 1.54 0.27 to 8.71 0.62 - - - 
  COPD 2.80 1.20 to 6.56 0.018 - - - 
  Asthma 0.51 0.17 to 1.52 0.23 - - - 
  Other 2.21 0.88 to 5.55 0.093 - - - 
Chronic renal disease  3.68 0.80 to 17.02 0.095 - - - 
Diabetes mellitus 1.76 0.90 to 3.44 0.10 - - - 
Abbreviations: CI indicates confidence interval; COPD, chronic obstructive pulmonary 
disease; OR, odds ratio. Data are shown as estimated ORs (95% CIs) of the explanatory 
variables in the sepsis group. OR is defined as the probability of being in the sepsis 
group divided by the probability of being in the no-sepsis group. The P-values are 
based on the null hypothesis that all ORs relating to an explanatory variable equal 
unity (no effect). a The variables analyzed in the univariate analysis were as follows: 
age, gender, smoking status, alcohol consumption, influenza vaccine, pneumococcal 
vaccine, previous inhaled corticosteroids, previous systemic corticosteroids, previous 
antibiotic in last week, chronic pulmonary disease, chronic cardiovascular disease, 
chronic renal disease, chronic liver disease, diabetes mellitus, chronic neurologic 
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